Office of the Dean
A Message from Dean Laurie Glimcher
“Making patients the center of everything we do at Weill Cornell is our ultimate goal, driving us to deliver the best patient care and novel therapeutics and discover better ways to fight human disease.”
Everyday as Dean, I continue to discover the greatness that is Weill Cornell Medical College. From our classrooms to our research laboratories I experience the remarkable energy and camaraderie that underpin a culture of collaboration and achievement at our institution.
More than 1,000 medical, graduate, and MD-PhD students at Weill Cornell train alongside our world-class physicians who provide comprehensive patient care in affiliation with NewYork-Presbyterian Hospital, one of the top-ranked hospitals in the country.
The scientific endeavors of Weill Cornell's faculty span an amazing range of disciplines across the research continuum. Their work is further advanced through our innovative collaborations and groundbreaking partnerships with institutions of note – from The Rockefeller University in our own neighborhood to Cornell University in Ithaca, The Methodist Hospital Research Institute in Texas, and as far away as our medical school in Qatar, to name just a few.
Making patients the center of everything we do at Weill Cornell is our ultimate goal, driving us to deliver the best patient care and novel therapeutics and discover better ways to fight human disease. Critical to continuing to develop these new treatments is the ability of our clinicians, translational researchers, and basic scientists to meld ideas and share discoveries. Our interdisciplinary model is the future of biomedicine and we are transforming the way that medical research is conducted.
At Weill Cornell, a solid foundation is in place to further the institution as a world-class research enterprise. Thanks to the overwhelming success of our current $1.3 billion Discoveries that Make a Difference Campaign, in late 2013, we will open the Belfer Research Building, ushering in a new era in biomedical research. The building will double the Medical College's available research space and through the Research Leads to Cures initiative we will recruit some 30 top-tier physician-scientists who will become the next generation of clinical and research leaders.
Health care in this country is facing a watershed moment, and the challenges posed will require bold new ideas and a commitment to excellence. Today, we have a unique opportunity available to very few American medical colleges: to bend the curve in clinical care, graduate education and biomedical research. I am delighted to be here at this pivotal juncture in the history of Weill Cornell Medical College.
Laurie H. Glimcher, M.D.
Stephen and Suzanne Weiss Dean of Weill Cornell Medical College
Provost for Medical Affairs, Cornell University
Stephen and Suzanne Weiss Dean of Weill Cornell Medical College & Provost for Medical Affairs, Cornell University
Dean in the News
(April 28, 2014)
(July 16, 2014)
IWhen I was in high school and college, one of my favorite activities was acting in student productions. Before deciding to go to medical school, I even toyed with the idea of becoming an actress, but I knew I didn't really have the talent to make it professionally. Living in New York, I love being able to see so much great theater and to indulge another one of my interests, the opera. Sometimes I don't even have to go to...
(May 29, 2014)
Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, gave the following address to the Class of 2014 during commencement on May 29 at Carnegie Hall.
Interview with the Dean
(April 10, 2014)
Dr. Laurie H. Glimcher, dean of Weill Cornell Medical College, speaks with Dr. Hazel Szeto, professor of pharmacology. Dr. Szeto's research focuses on mitochondria, the cells' powerhouse. A peptide Dr. Szeto created with a colleague has shown promise in treating what she calls "brownout diseases" -- Alzheimer's, heart failure and diabetes among them -- in which this "power plant" doesn't function properly. In 2006, Dr. Szeto founded the biopharmaceutical company Stealth Peptides. Its first drug candidate, Bendavia, is in clinical trials.